Baloxavir Marboxil CAS 1985606-14-1 Raw Powder Materials

CAS: 1985606-14-1

MF: C27H23F2N3O7S

Specification​: 99% min Baloxavir Marboxil

Sample: Baloxavir Marboxil Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Portal:https://henrikang.en.made-in-china.com/

Baloxavir Marboxil Usage and Synthesis.

Baloxavir Marboxil Usage and Synthesis:

The anti-influenza drug baloxavir is a precursor drug that enters the body and is hydrolyzed to the active substance baloxavir, which exerts anti-influenza viral activity. Baloxavir is a anti-influenza drug with a novel mechanism of action that inhibits the cap-dependent nucleic acid endonuclease in influenza viruses, thereby blocking the transcription of the virus' own mRNA. Baloxavir has a half-life of approximately 80 hours and requires only one dose.
Baloxavir Marboxil is a new antiviral drug that was approved by the FDA in 2018 for the treatment of influenza virus infections. Baloxavir Marboxil Powder is an oral drug that treats influenza virus infection by inhibiting its protein synthesis. Baloxavir Marboxil Raw Materials is an innovative CAP-dependent endonuclease inhibitor and one of the few new drugs in the world that can inhibit the proliferation of influenza virus.

Application/Function of Baloxavir Marboxil.

Baloxavir Marboxil has many advantages over traditional anti-influenza drugs. First, it has a much faster therapeutic effect, providing significant relief of flu symptoms within 24 hours. Second, it can be administered orally, avoiding inconvenient treatment options such as injections. In addition, baloxavir is less resistant to the drug and can effectively avoid resistance to the drug by the influenza virus.

Baloxavir is indicated for patients ≥12 years of age who develop acute uncomplicated influenza, no more than 48 h after the onset of symptoms. Limitations of dosing should be noted: influenza viruses change over time and factors such as virus type and subtype exist that may diminish the clinical efficacy of antivirals in the event of viral resistance and changes in viral pathogenicity, and available information on the susceptibility of locally prevalent virus strains to the drug should be considered when deciding whether to take basaloxavir.

However, there are some shortcomings of baclofenoxate.

• First, it can only treat influenza virus infections and is not effective against other viral infections.
• Second, its use is limited to adult patients aged 12 years and older.
• In addition, the side effects of baloxavirate require attention and may cause adverse reactions such as nausea, vomiting, and headache.

Mechanism of action of Baloxavir Marboxil:

Baloxavir Marboxil is a novel antiviral drug that treats influenza virus infections by inhibiting the protein synthesis of the influenza virus. It has the advantages of rapidity, convenience and low drug resistance, but also has the disadvantages of limited use and side effects. When using baloxsavir, it is necessary to administer the drug reasonably according to the doctor's advice to ensure efficacy and safety.

Baloxavir ester is a precursor drug that enters the body and is hydrolyzed to the active substance baloxavir, which exerts anti-influenza virus activity. Baloxavir is an anti-influenza drug with a novel mechanism of action that inhibits the cap-dependent nucleic acid endonuclease in the influenza virus, thereby blocking the transcription of the virus' own mRNA. Baloxavir has a half-life of approximately 80 hours and requires only one dose.

Preparation process of Baloxavir Marboxil.

The mechanism of action of baloxavir marboxil is to treat influenza virus infection by inhibiting the protein synthesis of the influenza virus. Its primary target is the nucleic acid polymerase of the influenza virus, an enzyme essential to the replication process of the influenza virus. Baloxavir ester binds to this enzyme and prevents it from working properly, thereby inhibiting the replication and spread of the influenza virus.

Baloxavir ester is a small molecule precursor drug with a different mechanism of action than currently available antiviral therapies, as it selectively inhibits cap-dependent nucleic acid endonucleases, which can block polymerase function and influenza virus mRNA replication. The mechanism of action of established anti-influenza drugs is through targeting neuraminidases. In contrast to these drugs, baloxavir targets a much earlier stage of the viral replication cycle.